City Of Hope

William Dale, MD, PhD, FASCO, has experienced a range of emotions since learning he’d receive the B.J. Kennedy Geriatric Oncology Award at this year’s ASCO Annual Meeting.

A phase 1 trial showed chimeric antigen receptor T-cell therapy may hold promise for the treatment of glioblastoma.

Sumanta K. Pal, MD, FASCO, expressed a mix of emotions.

Tumor mutational burden may help predict benefit of immune checkpoint inhibitor therapy for men with metastatic castration-resistant prostate cancer, according to retrospective study results.

MRIs and lumbar punctures may not provide enough therapeutic value to be standard-of-care diagnostic tests in patients suffering neurologic symptoms following chimeric antigen receptor T-cell therapy.

Arya Amini, MD, still remembers sitting on the steps outside of his dean’s office at University of California, Irvine, more than a decade ago, prepared to race inside in case he did not get matched with a radiation oncology residency.

Liquid biopsy could provide enhanced information about chimeric antigen receptor T-cell therapy compared with normally used DNA, RNA and protein assays, according to findings published in Journal for ImmunoTherapy of Cancer.

Limiting eligibility criteria, recruiting trusted community messengers and reducing financial burdens can help improve diversity of clinical trial enrollees, a panel of professionals said during a Friends of Cancer Research webinar.

Healio will present its third annual Disruptive Innovators Awards for oncology/hematology this spring.

There are significant differences in response to treatment and survival outcomes for certain racial and ethnic groups among patients with resected stage II or stage III gastric cancer, study findings published in JAMA Network Open showed.